Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference
August 21 2019 - 8:00AM
Business Wire
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy
company, today announced that its Chairman and Chief Executive
Officer, Rodney Varner, is scheduled to present at the 4th Annual
Disruptive Growth Conference hosted by ReedSmith in New York City
on September 4, 2019.
Genprex will present at the 4th Annual Disruptive Growth
Conference as follows:
Date: Wednesday, September 4, 2019
Time: 5:00-5:15 p.m. EDT
Venue: ReedSmith Offices, 599 Lexington Avenue, 22nd
Floor, New York City
Room: Presentation Room A/B
The 2019 Disruptive Growth Conference will offer the exclusive
opportunity to discover growth companies with disruptive
technologies and business models covering the following sectors:
communications, consumer, energy/alternative energy, healthcare,
industrial, life sciences, natural resources and technology.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. Visit the company’s web site at www.genprex.com or
follow Genprex on Twitter at twitter.com/genprex, Facebook at
facebook.com/genprexinc, and LinkedIn at
linkedin.com/company/genprex.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effects of Oncoprex on cancer. Risks and uncertainties
associated with Genprex and its lead product candidate Oncoprex are
described more fully under the caption “Risk Factors” and elsewhere
in our filings and reports with the United States Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. We undertake no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190821005040/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024